Labeling Changes Possible For HCV Direct-Acting Antivirals As EMA Probes HBV Reactivation
This article was originally published in SRA
Executive Summary
The European Medicines Agency has begun a review of the direct-acting antivirals (DAAs) for hepatitis C in light of a number of recent cases showing that hepatitis B virus has been reactivated in some HCV patients treated with the newer products1.
You may also be interested in...
EMA Committee Urges Warning About Hep B Reactivation In Patients Taking DAAs
The European Medicines Agency’s pharmacovigilance committee wants manufacturers of the direct-acting antivirals for hepatitis C to include a warning about the possibility of hepatitis B reactivation in patients who carry both viruses.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.